H02 Stock Analysis: HAW PAR | SG
Drug Manufacturers - General | SG, Singapore | Market Cap: 3.431m SGD | 12M Return: 8.7% | SG1D25001158 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.48M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Haw Par Corporation Limited is a Singapore-based holding company that operates across three main segments: healthcare, leisure, and property. Its core healthcare business manufactures and distributes topical analgesic products under the well-established Tiger Balm and Kwan Loong brands, sold across Singapore, ASEAN, other Asian markets, and internationally. Topical analgesics are over-the-counter pain relief products typically applied to the skin for muscle and joint discomfort.
Beyond healthcare, the company owns and operates oceanariums offering family and tourist-oriented leisure activities, and maintains a portfolio of investment and development properties, including leased office space. It also invests in quoted securities, adding a financial investment component to its diversified earnings base. Founded in 1969 and headquartered in Singapore, Haw Par operates with a conglomerate-style structure spanning consumer health, tourism, and real estate.
- Tiger Balm pricing power supports healthcare margins
- Quoted securities portfolio volatility impacts reported earnings
- Investment property revaluations boost net asset value
| Net Income: 265.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.07 > 1.0 |
| NWC/Revenue: 1.81k% < 20% (prev 1.58k%; Δ 226.9% < -1%) |
| CFO/TA 0.01 > 3% & CFO 57.1m > Net Income 265.5m |
| Net Debt (-791.0m) to EBITDA (57.0m): -13.88 < 3 |
| Current Ratio: 52.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 55.99% > 18% (prev 54.77%; Δ 1.22% > 0.5%) |
| Asset Turnover: 5.29% > 50% (prev 5.72%; Δ -0.43% > 0%) |
| Interest Coverage Ratio: 33.23 > 6 (EBIT TTM 50.6m / Interest Expense TTM 1.52m) |
| A: 0.94 (Total Current Assets 4.25b - Total Current Liabilities 81.3m) / Total Assets 4.42b |
| B: 0.35 (Retained Earnings 1.53b / Total Assets 4.42b) |
| C: 0.01 (EBIT TTM 50.6m / Avg Total Assets 4.35b) |
| D: 33.83 (Book Value of Equity 4.29b / Total Liabilities 126.8m) |
| Altman-Z'' = 42.92 = AAA |
| DSRI: 0.75 (Receivables 33.8m/47.8m, Revenue 230.0m/244.8m) |
| GMI: 0.98 (GM 54.77% / 55.99%) |
| AQI: 0.53 (AQ_t 0.03 / AQ_t-1 0.05) |
| SGI: 0.94 (Revenue 230.0m / 244.8m) |
| TATA: 0.05 (NI 265.5m - CFO 57.1m) / TA 4.42b) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of August 25, 2026, the stock is trading at SGD 14.87 with a total of 309,400 shares traded. Over the past week, the price has changed by -0.92%, over one month by -6.80%, over three months by -8.89% and over the past year by +8.67%.
Current recommended Stop Loss: 14.50 (which is 2.5% or 1.5 ATR below the current price).
HAW PAR has no consensus analysts rating.
P/E Trailing = 14.9038
P/E Forward = 15.8228
P/S = 14.9204
P/B = 0.8239
Revenue TTM = 230.0m SGD
EBIT TTM = 50.6m SGD
EBITDA TTM = 57.0m SGD
Long Term Debt = 44.3m SGD (from longTermDebt, last quarter)
Short Term Debt = 44.3m SGD (from shortLongTermDebt, last quarter)
Debt = 422k SGD (Leases only: 422k)
Net Debt = -791.0m SGD (calculated: Debt 422k - CCE 791.4m)
Enterprise Value = 2.64b SGD (3.43b + Debt 422k - CCE 791.4m)
Interest Coverage Ratio = 33.23 (Ebit TTM 50.6m / Interest Expense TTM 1.52m)
EV/FCF = 48.00x (Enterprise Value 2.64b / FCF TTM 55.0m)
FCF Yield = 2.08% (FCF TTM 55.0m / Enterprise Value 2.64b)
FCF Margin = 23.92% (FCF TTM 55.0m / Revenue TTM 230.0m)
Net Margin = 115.4% (Net Income TTM 265.5m / Revenue TTM 230.0m)
Gross Margin = 55.99% ((Revenue TTM 230.0m - Cost of Revenue TTM 101.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.60 (Enterprise Value 2.64b / Total Assets 4.42b)
Interest Expense / Debt = 360.9% (Interest Expense 1.52m / Debt 422k)
Taxrate = 5.75% (16.2m / 281.6m)
NOPAT = 47.7m (EBIT 50.6m * (1 - 5.75%))
Current Ratio = 52.24 (Total Current Assets 4.25b / Total Current Liabilities 81.3m)
Debt / Equity = 0.00 (Debt 422k / totalStockholderEquity, last quarter 4.29b)
Debt / EBITDA = -13.88 (Net Debt -791.0m / EBITDA 57.0m)
Debt / FCF = -14.38 (Net Debt -791.0m / FCF TTM 55.0m)
Total Stockholder Equity = 4.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.11% (Net Income 265.5m / Total Assets 4.42b)
RoE = 6.55% (Net Income TTM 265.5m / Total Stockholder Equity 4.05b)
RoCE = 1.23% (EBIT 50.6m / Capital Employed (Equity 4.05b + L.T.Debt 44.3m))
RoIC = 1.10% (NOPAT 47.7m / Invested Capital 4.33b)
WACC = 6.19% (E(3.43b)/V(3.43b) * Re(6.19%) + (debt cost/tax rate unavailable))
Discount Rate = 6.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.39 | Cagr: 0.05%
[DCF] Terminal Value 76.58% ; FCFF base≈53.1m ; Y1≈57.5m ; Y5≈70.6m
[DCF] Fair Price = 8.46 (EV 1.08b - Net Debt -791.0m = Equity 1.87b / Shares 221.4m; r=8.35% [WACC [floored]]; 5y FCF grow 9.30% → 2.50% )
Revenue Correlation: -13.40 | Revenue CAGR: -0.45% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.25 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+4.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=1.28 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+2.8% | GrowthRev=+6.5%